Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7
Authors:
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Tumor cells cotransduced with B7.1 and γ-IFN induce effective rejection of established parental tumorGene Therapy, 1999
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.Journal of Experimental Medicine, 1996
- Cytokine gene-modified vaccines in the therapy of cancerPharmacology & Therapeutics, 1996
- Tumor cells cotransfected with interleukin‐7 and B7.1 genes induce CD25 and CD28 on tumor‐infiltrating T lymphocytes and are strong vaccinesEuropean Journal of Immunology, 1995
- Immunization of Mice with Allogeneic Fibroblasts Genetically Modified for Interleukin-2-Secretion and Expression of Melanoma-Associated Antigens Stimulate Predetermined Classes of Anti-Melanoma Effector CellsJournal of Immunotherapy, 1994
- Immunization with interleukin‐2‐secreting allogeneic mouse fibroblasts expressing melanoma‐associated antigens prolongs the survival of mice with melanomaInternational Journal of Cancer, 1993
- Molecular Mechanisms Used by Tumors to Escape Immune RecognitionJournal of Immunotherapy, 1993
- Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma CellsScience, 1993
- Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.Journal of Experimental Medicine, 1990